SCHEDULE: Armistice Capital Discloses 9.22% Stake in Ironwood Pharma

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares, representing 9.22% of Ironwood Pharmaceuticals, Inc.'s Class A common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold a significant stake in Ironwood Pharmaceuticals, Inc.
• The filing reports beneficial ownership of 15,028,000 shares of Class A common stock.
• This holding represents 9.22% of the total class of securities.
• The reporting date for this ownership is March 31, 2026.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The Master Fund disclaims beneficial ownership due to the investment management agreement with Armistice Capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance data.

Positives

• Armistice Capital, LLC and Steven Boyd have established a substantial beneficial ownership of 9.22% in Ironwood Pharmaceuticals, Inc., indicating confidence in the company's value or future prospects.
• The clear reporting of shared voting and dispositive power suggests a well-defined investment strategy and control structure.

Negatives

• The Master Fund, the direct holder of the shares, explicitly disclaims beneficial ownership, which could imply a lack of direct control or strategic alignment beyond the investment management agreement.

Risks

• Potential for increased scrutiny from regulatory bodies or the market regarding the significant stake held by Armistice Capital and Steven Boyd.
• The disclaimer of beneficial ownership by the Master Fund could indicate potential complexities in the governance or strategic decision-making related to these shares.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future financial performance or strategic direction of Ironwood Pharmaceuticals, Inc. It solely reports on beneficial ownership.

Management Comments

• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the pharmaceutical sector, often indicating activist investor interest or strategic positioning by institutional investors. This filing places Ironwood Pharmaceuticals within this context of active institutional investment.

Stakeholder Impact

• Shareholders: The significant stake may influence future corporate actions or strategic decisions, potentially impacting shareholder value.
• Management: The increased ownership by a substantial investor may lead to closer scrutiny of management's performance and strategy.
• Creditors: While not directly impacted by this ownership filing, significant changes in corporate control or strategy could indirectly affect financial stability.

Next Steps

• Continued monitoring of Armistice Capital's and Steven Boyd's holdings and any future filings related to Ironwood Pharmaceuticals, Inc.

Key Dates

Keywords

Ironwood Pharmaceuticals, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management